DPP-4 Inhibitors
9,577 views
Diabetes Drugs (Old)
- Insulin Preparations
- Metformin
- Glitazones / Thiazolidinediones
- First-Gen Sulfonylureas
- Second-Gen Sulfonylureas
- Meglitinides
- GLP-1 Analogs
- DPP-4 Inhibitors
- alpha-Glucosidase Inhibitors
- Pramlintide
Summary
DPP-4 inhibitors are drugs used in the treatment of type 2 diabetes. They work by inhibiting the degradation of incretins—notably GLP-1. GLP-1 leads to glucose-dependent insulin release, which has a decreased risk of causing hypoglycemia because it only releases insulin when glucose levels are high. Last but not least, DPP-4 inhibitors may cause mild urinary and respiratory infections.
Key Points
- DPP-4 Inhibitors
- Drugs end in -gliptin
- Linagliptin
- Saxagliptin
- Sitagliptin
- Alogliptin
- Clinical Use
- Type II Diabetes
- Mechanism
- DPP-4 inhibition → increased incretins
- Increased GLP-1
- Also increases GIP and other off-targets
- Increase glucose-dependent insulin release
- Decrease glucagon release
- Delay gastric emptying
- Increase satiety
- DPP-4 inhibition → increased incretins
- Adverse Effects
- Mild urinary / respiratory infections
- Generally weight neutral (i.e. no weight gain)
- Drugs end in -gliptin